Conference abstractPublished 10 Aug 2017
Challenges in assessing therapeutic equivalence of nanosimilars
Vifor Pharma Ltd, Switzerland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Showing therapeutic equivalence of nanomedicine follow on products to a reference drug is like for biosimilars more challenging than for low molecular weight drugs. The pharmacokinetics and especially the bio-distribution can be among other parameters which depend on the size/size distribution and composition of the nanoparticle, having implications on the efficacy and safety of the drug. Today, the interaction of these nanoparticles with the body is not fully understood and the clinically meaningful physicochemical parameters are only partially identified. In two clinical studies of chronic kidney disease patients depending on hemodialysis, a lack of therapeutic equivalence was demonstrated for the first time for a nanomedicine, namely VenoferÃ?® (iron sucrose), a nano particulate iron preparation for i.v use and it follows on products or better called iron sucrose similars (ISS)-approved on a generic pathway in Europe. Upon switching from the originator iron sucrose to the ISS, a rapid drop in Hb level and iron parameters was observed and higher doses of i.v iron as well as ESA was required to stabilize the patientâÂ?Â?s Hb levels. Further clinical reports also showed different safety outcomes such as increased levels of inflammation markers in hemodialysis patients and a significantly higher number of adverse events in gynecology patients. The generic paradigm, lacks the clinical and non-clinical safety and efficacy requirements, is therefore not appropriate to assess nanomedicine follow-ons. Although ISS share the international nonproprietary name with the originator, they can exhibit clinically meaningful differences. Alarmed by these findings, the FDA and EMA have issued draft guidelines and reflection papers that propose a multi-step in vitro, non-clinical and clinical testing to evaluate the extent of similarity as a pre-requisite to define the therapeutic position and the interchangeability or switchability of such nanomedicines.
Subjects
NanotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- SubjectNanotechnology
- BylineArticles whose byline prints “Beat Fluhmann”
